Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Novel adenovirus encoded virus-like particles displaying the placental malaria associated VAR2CSA antigen

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{ed56e8cac48a40b99e62c13d1a68e629,
title = "Novel adenovirus encoded virus-like particles displaying the placental malaria associated VAR2CSA antigen",
abstract = "The malaria parasite Plasmodium falciparum presents antigens on the infected erythrocyte surface that bind human receptors expressed on the vascular endothelium. The VAR2CSA mediated binding to a distinct chondroitin sulphate A (CSA) is a crucial step in the pathophysiology of placental malaria and the CSA binding region of VAR2CSA has been identified as a promising vaccine target against placental malaria. Here we designed adenovirus encoded virus-like particles (VLP) by co-encoding Simian Immunodeficiency Virus (SIV) gag and VAR2CSA. The VAR2CSA antigen was fused to the transmembrane (TM) and cytoplasmic tail (CT) domains of either the envelope protein of mouse mammary tumour virus (MMTV) or the hemagglutinin (HA) of influenza A. For a non-VLP incorporation control, a third design was made where VAR2CSA was expressed without TM-CT domains. In the primary immunogenicity study in Balb/c mice, VAR2CSA fused to HA TM-CT was significantly superior in inducing ID1-ID2a specific antibodies after the first immunization. A sequential study was performed to include a comparison to the soluble VAR2CSA protein vaccine, which has entered a phase I clinical trial (NCT02647489). The results revealed the induction of higher antibody responses and increased inhibition of parasite binding to CSA using either VAR2CSA HA TM-CT or VAR2CSA MMTV TM-CT as priming vaccines for protein double-boost immunizations, compared to protein prime-double boost regimen. Analysis of pooled serum samples on peptide arrays revealed a unique targeting of several epitopes in mice that had been primed with VAR2CSA HA TM-CT. Consequently, modification of VLP anchors is an important point of optimization in virus-encoded retroviral VLP-based vaccines, and adenovirus VLPs boosted by recombinant proteins offer hope of increasing the levels of protective VAR2CSA specific antibodies.",
keywords = "Adenoviridae, Animals, Antibodies, Protozoan, Antigens, Protozoan, Chondroitin Sulfates, Erythrocytes, Female, Gene Products, gag, Genetic Vectors, Hemagglutinin Glycoproteins, Influenza Virus, Humans, Immunization, Malaria Vaccines, Malaria, Falciparum, Mammary Tumor Virus, Mouse, Mice, Mice, Inbred BALB C, Placenta, Plasmodium falciparum, Pregnancy, Protein Binding, Recombinant Fusion Proteins, Simian Immunodeficiency Virus, Vaccines, Virus-Like Particle, Journal Article, Research Support, Non-U.S. Gov't",
author = "Andersson, {Anne-Marie C} and Mafalda Resende and Ali Salanti and Nielsen, {Morten A} and Holst, {Peter J}",
note = "Copyright {\circledC} 2017 Elsevier Ltd. All rights reserved.",
year = "2017",
month = "2",
day = "22",
doi = "10.1016/j.vaccine.2017.01.016",
language = "English",
volume = "35",
pages = "1140--1147",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier Ltd",
number = "8",

}

RIS

TY - JOUR

T1 - Novel adenovirus encoded virus-like particles displaying the placental malaria associated VAR2CSA antigen

AU - Andersson, Anne-Marie C

AU - Resende, Mafalda

AU - Salanti, Ali

AU - Nielsen, Morten A

AU - Holst, Peter J

N1 - Copyright © 2017 Elsevier Ltd. All rights reserved.

PY - 2017/2/22

Y1 - 2017/2/22

N2 - The malaria parasite Plasmodium falciparum presents antigens on the infected erythrocyte surface that bind human receptors expressed on the vascular endothelium. The VAR2CSA mediated binding to a distinct chondroitin sulphate A (CSA) is a crucial step in the pathophysiology of placental malaria and the CSA binding region of VAR2CSA has been identified as a promising vaccine target against placental malaria. Here we designed adenovirus encoded virus-like particles (VLP) by co-encoding Simian Immunodeficiency Virus (SIV) gag and VAR2CSA. The VAR2CSA antigen was fused to the transmembrane (TM) and cytoplasmic tail (CT) domains of either the envelope protein of mouse mammary tumour virus (MMTV) or the hemagglutinin (HA) of influenza A. For a non-VLP incorporation control, a third design was made where VAR2CSA was expressed without TM-CT domains. In the primary immunogenicity study in Balb/c mice, VAR2CSA fused to HA TM-CT was significantly superior in inducing ID1-ID2a specific antibodies after the first immunization. A sequential study was performed to include a comparison to the soluble VAR2CSA protein vaccine, which has entered a phase I clinical trial (NCT02647489). The results revealed the induction of higher antibody responses and increased inhibition of parasite binding to CSA using either VAR2CSA HA TM-CT or VAR2CSA MMTV TM-CT as priming vaccines for protein double-boost immunizations, compared to protein prime-double boost regimen. Analysis of pooled serum samples on peptide arrays revealed a unique targeting of several epitopes in mice that had been primed with VAR2CSA HA TM-CT. Consequently, modification of VLP anchors is an important point of optimization in virus-encoded retroviral VLP-based vaccines, and adenovirus VLPs boosted by recombinant proteins offer hope of increasing the levels of protective VAR2CSA specific antibodies.

AB - The malaria parasite Plasmodium falciparum presents antigens on the infected erythrocyte surface that bind human receptors expressed on the vascular endothelium. The VAR2CSA mediated binding to a distinct chondroitin sulphate A (CSA) is a crucial step in the pathophysiology of placental malaria and the CSA binding region of VAR2CSA has been identified as a promising vaccine target against placental malaria. Here we designed adenovirus encoded virus-like particles (VLP) by co-encoding Simian Immunodeficiency Virus (SIV) gag and VAR2CSA. The VAR2CSA antigen was fused to the transmembrane (TM) and cytoplasmic tail (CT) domains of either the envelope protein of mouse mammary tumour virus (MMTV) or the hemagglutinin (HA) of influenza A. For a non-VLP incorporation control, a third design was made where VAR2CSA was expressed without TM-CT domains. In the primary immunogenicity study in Balb/c mice, VAR2CSA fused to HA TM-CT was significantly superior in inducing ID1-ID2a specific antibodies after the first immunization. A sequential study was performed to include a comparison to the soluble VAR2CSA protein vaccine, which has entered a phase I clinical trial (NCT02647489). The results revealed the induction of higher antibody responses and increased inhibition of parasite binding to CSA using either VAR2CSA HA TM-CT or VAR2CSA MMTV TM-CT as priming vaccines for protein double-boost immunizations, compared to protein prime-double boost regimen. Analysis of pooled serum samples on peptide arrays revealed a unique targeting of several epitopes in mice that had been primed with VAR2CSA HA TM-CT. Consequently, modification of VLP anchors is an important point of optimization in virus-encoded retroviral VLP-based vaccines, and adenovirus VLPs boosted by recombinant proteins offer hope of increasing the levels of protective VAR2CSA specific antibodies.

KW - Adenoviridae

KW - Animals

KW - Antibodies, Protozoan

KW - Antigens, Protozoan

KW - Chondroitin Sulfates

KW - Erythrocytes

KW - Female

KW - Gene Products, gag

KW - Genetic Vectors

KW - Hemagglutinin Glycoproteins, Influenza Virus

KW - Humans

KW - Immunization

KW - Malaria Vaccines

KW - Malaria, Falciparum

KW - Mammary Tumor Virus, Mouse

KW - Mice

KW - Mice, Inbred BALB C

KW - Placenta

KW - Plasmodium falciparum

KW - Pregnancy

KW - Protein Binding

KW - Recombinant Fusion Proteins

KW - Simian Immunodeficiency Virus

KW - Vaccines, Virus-Like Particle

KW - Journal Article

KW - Research Support, Non-U.S. Gov't

U2 - 10.1016/j.vaccine.2017.01.016

DO - 10.1016/j.vaccine.2017.01.016

M3 - Journal article

VL - 35

SP - 1140

EP - 1147

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 8

ER -

ID: 52820189